WO2023090715A3 - Method and system for predicting skin irritation information for prescription containing retinol, and anti-irritant or anti-inflammatory composition against retinol, comprising irritation reducing agent as active ingredient - Google Patents

Method and system for predicting skin irritation information for prescription containing retinol, and anti-irritant or anti-inflammatory composition against retinol, comprising irritation reducing agent as active ingredient Download PDF

Info

Publication number
WO2023090715A3
WO2023090715A3 PCT/KR2022/017219 KR2022017219W WO2023090715A3 WO 2023090715 A3 WO2023090715 A3 WO 2023090715A3 KR 2022017219 W KR2022017219 W KR 2022017219W WO 2023090715 A3 WO2023090715 A3 WO 2023090715A3
Authority
WO
WIPO (PCT)
Prior art keywords
retinol
irritation
prescription
reducing agent
information
Prior art date
Application number
PCT/KR2022/017219
Other languages
French (fr)
Korean (ko)
Other versions
WO2023090715A2 (en
Inventor
김경회
강성수
신중곤
김윤관
전승현
김주현
이선주
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210179988A external-priority patent/KR20230072354A/en
Priority claimed from KR1020220021662A external-priority patent/KR20230073062A/en
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Priority to CN202280074160.3A priority Critical patent/CN118201591A/en
Publication of WO2023090715A2 publication Critical patent/WO2023090715A2/en
Publication of WO2023090715A3 publication Critical patent/WO2023090715A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method and a system for predicting whether a prescription containing retinol will cause irritation, selecting a prescription on the basis of the prediction of whether irritation will be induced, and recommending a product matching the selected prescription. According to the present invention, a personally optimized prescription and product information may be selected and provided by predicting whether a product causes irritation, which may differ for each individual depending on the genetic information thereof, even for the same product. In addition, the present invention relates to: an anti-irritant or anti-inflammatory composition against retinol, comprising an irritation reducing agent as an active ingredient; and an information provision method for selecting a personalized irritation reducing agent for reducing irritation or inflammation caused by retinol, the method comprising a step for checking a polymorphic site of a retinol sensitivity single nucleotide polymorphism marker.
PCT/KR2022/017219 2021-11-17 2022-11-04 Method and system for predicting skin irritation information for prescription containing retinol, and anti-irritant or anti-inflammatory composition against retinol, comprising irritation reducing agent as active ingredient WO2023090715A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280074160.3A CN118201591A (en) 2021-11-17 2022-11-04 Method and system for predicting skin irritation information of formulation containing retinol, and composition for anti-irritation or anti-inflammatory for retinol containing irritation-relieving agent as effective ingredient

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2021-0158186 2021-11-17
KR20210158154 2021-11-17
KR20210158186 2021-11-17
KR10-2021-0158154 2021-11-17
KR10-2021-0179988 2021-12-15
KR1020210179988A KR20230072354A (en) 2021-11-17 2021-12-15 Prediction Method and System for Presense or Absense of Irritation in Prescriptions comprising Retinol
KR10-2022-0021662 2022-02-18
KR1020220021662A KR20230073062A (en) 2021-11-17 2022-02-18 Composition for anti-irritation or anti-inflammatory by retinol comprising an irritant reliever as an active ingredient

Publications (2)

Publication Number Publication Date
WO2023090715A2 WO2023090715A2 (en) 2023-05-25
WO2023090715A3 true WO2023090715A3 (en) 2023-07-06

Family

ID=86397429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/017219 WO2023090715A2 (en) 2021-11-17 2022-11-04 Method and system for predicting skin irritation information for prescription containing retinol, and anti-irritant or anti-inflammatory composition against retinol, comprising irritation reducing agent as active ingredient

Country Status (1)

Country Link
WO (1) WO2023090715A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150134455A (en) * 2014-05-21 2015-12-02 이창남 A device for providing customized cosmetic information and the method thereof
US20200321074A1 (en) * 2017-01-24 2020-10-08 Ha Tran Personalized cosmetic system
KR20210079229A (en) * 2019-12-19 2021-06-29 재단법인 제주테크노파크 A system for personal tailored cosmetic with improved customer satisfaction
KR20210081191A (en) * 2019-12-23 2021-07-01 주식회사 테라젠바이오 Biomarker for predicting skin sensitivity risk and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150134455A (en) * 2014-05-21 2015-12-02 이창남 A device for providing customized cosmetic information and the method thereof
US20200321074A1 (en) * 2017-01-24 2020-10-08 Ha Tran Personalized cosmetic system
KR20210079229A (en) * 2019-12-19 2021-06-29 재단법인 제주테크노파크 A system for personal tailored cosmetic with improved customer satisfaction
KR20210081191A (en) * 2019-12-23 2021-07-01 주식회사 테라젠바이오 Biomarker for predicting skin sensitivity risk and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARDING AMY L., MURDOCH CRAIG, DANBY SIMON, HASAN MD ZOBAER, NAKANISHI HIROFUMI, FURUNO TETSUO, HADAD SIRWAN, TURNER ROBERT, COLLE: "Determination of Chemical Irritation Potential Using a Defined Gene Signature Set on Tissue-Engineered Human Skin Equivalents", JID INNOVATIONS, vol. 1, no. 2, 1 June 2021 (2021-06-01), pages 100011, XP093073829, ISSN: 2667-0267, DOI: 10.1016/j.xjidi.2021.100011 *

Also Published As

Publication number Publication date
WO2023090715A2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
Dolati et al. Peripheral Th17/Treg imbalance in elderly patients with ischemic stroke
Singh et al. Parkinson's: a disease of aberrant vesicle trafficking
Dracheva et al. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia
WO2005122050A3 (en) Method for executing block orders of commodities
Xue et al. 1α, 25‐Dihydroxyvitamin D3 inhibits pro‐inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa
WO2004070676A8 (en) Acquiring, managing, distributing, and presenting contextual data relating to a known position for location-based services to and between users
WO2007120387A3 (en) Methods and systems for sharing or presenting member information
CA2498048A1 (en) Method and apparatus for publishing and monitoring entities providing services in a distributed data processing system
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008101229A3 (en) Method and system for providing contextual based medication dosage determination
WO2008042232A3 (en) Method and system for displaying genetic and genealogical data
WO2012177853A3 (en) Temporal task-based tab management
WO2003062423A3 (en) Method for inhibiting the expression of a target gene resulting from a chromosome aberration
WO2012009073A3 (en) Systems and methods for customizing product selections based on member parameters and providing the selections to members for purchase
Bromberg et al. Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic association and decreased frontal cortex mRNA levels
WO2008010077A3 (en) System and method for influencing public opinion
EA201390393A1 (en) TWO-DIMENSIONAL IDENTIFICATION DIAGRAM, A PRODUCT WHICH HAS SUCH A DIAGRAM, AND METHODS OF OBTAINING AND IDENTIFICATION
WO2007124356A3 (en) Methods and systems for providing evidence based evaluations of medical treatments
MX2019008978A (en) A method of predicting a traffic behaviour in a road system.
Carotenuto et al. Predictors of nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study
WO2023090715A3 (en) Method and system for predicting skin irritation information for prescription containing retinol, and anti-irritant or anti-inflammatory composition against retinol, comprising irritation reducing agent as active ingredient
WO2005038567A3 (en) Internet commerce access security system and method
WO2007062408A3 (en) Systems and methods of conducting clinical research
WO2006076472A3 (en) Method and system for providing customized recommendations to users
BRPI0516933A (en) methods for isolating human haptoglobin, individual human hp isoforms, and human albumin and haptoglobin from human cohn fraction v, and

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22895922

Country of ref document: EP

Kind code of ref document: A2